Will the FDA approve any psychedelic substance for medical use this year?
Health & MedicineOne-Off2mo
KalshiCheck availabilityKYC requiredVerified resolution dataWell calibratedSelected book midpoint
No · —
Loading selected book…
—
Stored price
No 84%
No 84%Market quality
68 / 100
Medium quality24h Volume
$335.4
Open interest
$96.9K
High open interestBid / Ask
— / —
NoSpread
—
Market data
Updated 8 minutes ago
Jul 17, 25, 2:00 PM UTCJan 1, 27, 4:59 AM UTC
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Venue terms
Source: Kalshi
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Early close:
- Yes
- Settlement timer:
- 30m (informational)
Market depth · No
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Will the FDA approve any psychedelic substance for medical use before 2028?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill a psychedelic substance get de-scheduled by the US by 2030?
Manifold MarketsWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurRules
This outcome's exact rule is not available.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca. Important information: For purposes of this Contract: The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion. "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion. Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance. New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.
Rules for each outcome
- No
- This outcome's exact rule is not available.
- Yes
- This outcome's exact rule is not available.
